Dr. Pallawi Torka, MD

Dr. Torka practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Torka's NPI, 1265744643, was assigned on July 13, 2010. Dr. Torka graduated from Jawaharlal Institute of Postgraduate Medical Education and Research in 2006. Dr. Torka holds New York license 284568.

Dr. Torka's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Torka's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Torka is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Torka to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Torka practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Torka's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Torka is licensed in New York.

CMS data shows 755 Medicare services from Dr. Torka across 7 procedure codes in 2024, for 211 Medicare patients. Medicare paid $69,487 for them.

CMS counts 211 Medicare patients who saw Dr. Torka in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Torka's median patient age at 74, with 51% women.

In 2024, Dr. Torka wrote 479 Medicare Part D claims for 73 patients. 72% of them were for generic drugs. CMS names the drug for 356 of them, across 9 drugs with 11 or more claims each, at $1,555,478 in total drug cost. In 2023, CMS named 114 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Torka for performance year 2024, reported as part of a group. Dr. Torka accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Torka as offering telehealth.

Dmand AI links 76 papers to Dr. Torka, published from 2012 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Hodgkin Disease. Dr. Torka has published most often in Blood Adv. Dr. Torka's most frequent co-authors are Reem Md Karmali, MD, Francisco J. Hernandez-Ilizaliturri, MD and Kevin Andrew David, MD.

Dmand AI links Dr. Torka to 6 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell. ECOG-ACRIN Cancer Research Group sponsors the most, 2.

CMS Open Payments shows 50 general payments to Dr. Torka from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Seagen Inc. paid the most, $13,324. It also lists 4 research payments totaling $5,355 from 2024 to 2025.

Dr. Torka graduated from Jawaharlal Institute of Postgraduate Medical Education and Research in 2006.